Transplantation & Immunosuppression

Immunosuppression (IS) is administered to kidney transplant recipients to prevent rejection episodes and loss of the renal allograft. Most centers rely on a triple IS after induction with either interleukin‑2 receptor antibodies or antithymocyte globulin. The most frequently used substances for maintenance IS are glucocorticoids, antimetabolites, mTOR inhibitors (mTORi), calcineurin inhibitors (CNI) and the costimulation blocker belatacept. Guidelines recommend a triple combination consisting of CNIs, antimetabolites and corticosteroids for the majority of patients. The long-term risk for malignancy in general is increased in solid organ recipients compared to the general population. Modification of IS may result in reduced risk for non-melanoma skin cancers but results in higher graft rejection rates and in the case of mTORi, deaths. In the case of posttransplantation lymphoproliferative disorders (PTLD) treatment options are reduction of IS, rituximab, chemotherapy, radiation therapy or a combination of these. The optimal protocol has not yet been established and depends on patient age and status, tumor load, laboratory findings, organ functions (heart, kidney, liver) and PTLD subtype. Posttransplantation diabetes mellitus is a frequent complication after kidney transplantation. Tacrolimus more than cyclosporine A.


    Related Conference of Transplantation & Immunosuppression

    October 25-26, 2023

    11th World Congress on Epidemiology & Public Health

    Nova Scotia, Canada
    November 15-16, 2023

    27th European Nephrology Conference

    Barcelona, Spain
    November 20-21, 2023

    22nd Annual Conference on Urology and Nephrological Disorders

    Amsterdam, Netherlands
    February 22-23, 2024

    20th World Nephrology Conference

    Zurich, Switzerland

    Transplantation & Immunosuppression Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in